La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Moleculin Biotech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Moleculin Biotech..

Moleculin Biotech (NASDAQ:MBRX) Azioni, Catena delle Opzioni

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin Biotech Inc

Press Releases

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

News

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

Moleculin Issues New Positive AML Overall Survival Data:

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial

Penny Stocks

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

AKTX

AMIX

CNSP

MBRX

NUWE

NVNO

SNTI

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Edesa Biotech

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

FibroBiologics

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Geovax Labs

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Leap Therapeutics

Lisata Therapeutics

MetaVia

Nanoviricides

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Q32 Bio

Rallybio

SAB Biotherapeutics

Synlogic

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

HC Wainwright & Co.

Maxim Group

Roth MKM

Comments

Moleculin Biotech

Moleculin Biotech (MBRX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO